Huawei to reportedly move its U.S. research center to Canada
By Akshay Kedari  Date: 2019-12-03

Huawei to reportedly move its U.S. research center to Canada

 

  • The U.S. plans to stop more foreign shipments to Huawei
  • Huawei will be manufacturing some 5G equipment outside China

The founder of Chinese communications giant Huawei Technologies has indicated that the company is planning to move its research center from the United States to Canada.

According to reliable sources, the decision was made after it was reported that United States had been contemplating expanding its power to be able to stop further foreign shipments of U.S technology-based products to the Chinese telecom equipment maker. The U.S. Commerce Department had reportedly blacklisted Huawei in May on the basis of national security concerns.

Ren Zhengfei, founder of Huawei Technologies, stated that the company’s center for research and development shall be relocated to Canada. He further added that the company will be manufacturing some 5G mobile network equipment outside China.

Zhengfei has been aiming to build new factories in Europe wherein they will develop fifth-generation (5G) networking equipment. This may assuage the fears that have stemmed from the U.S. allegations regarding its products that could be used for spying by China. The company has denied all such allegations and assured that it’s not a risk to the national security of the U.S.

Apparently, the firm had spent $510 million for its operations on the U.S. research unit in the previous year. The company has now laid off 600 workers to bring the number to nearly 250.

Chief Financial Officer of Huawei, Meng Wanzhou happens to be Ren’s daughter who got arrested by the Canadian Police the previous year on the basis of a warrant issued by the U.S. She has been fighting extradition to the United States for charges of having violated sanctions against Iran and has been out on bail. Huawei has denied all the charges and China has reportedly requested Canada for her release.

Ren further commented on the matter and said that this was an example of the obvious pollical interference coming from the United States. A Chinese envoy has been sent to Canada to visit the detained CFO of the company and file a request to correct a mistake.

 

Source Credit- https://www.nasdaq.com/articles/huawei-plans-to-shift-research-center-to-canada-from-u.s.-globe-and-mail-2019-12-02

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...

GVN adds EVIT Center and Chumakov as its new Centers of Excellence
GVN adds EVIT Center and Chumakov as its new Centers of Excellence
By Akshay Kedari

The Global Virus Network (GVN), an international coalition of medical virologists, has recently announced the addition of Australian and Russian researchers. GVN is adding the Center for EVIT (Emerging Viruses, Inflammation & Therapeutics) of th...

Wind Point Partners takes over RTIC to expand business portfolio
Wind Point Partners takes over RTIC to expand business portfolio
By Akshay Kedari

American private equity firm, Wind Point Partners has recently signed an acquisition deal with the one of the biggest direct-to-consumer (D2C) eCommerce providers of drinkware, RTIC. Reportedly, RTIC is Wind Point’s third acquisition of a famil...

Novartis reveals positive data from Phase III ORION trials of inclisiran
Novartis reveals positive data from Phase III ORION trials of inclisiran
By Akshay Kedari

Swiss multinational pharmaceutical firm, Novartis has recently announced results from its Phase III ORION-10 and -11 studies that focus on assessing the individual responses of patients on lowering low-density lipoprotein cholesterol (LDL-C) with inc...

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...